MONMOUTH JUNCTION, N.J., Nov. 15, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb^® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, today announced that Mr. Adrian Thomas has joined the company as Regional Sales Director of Western Europe.

Mr. Thomas is an experienced global sales executive based out of the United Kingdom and has been responsible for developing international sales and managing distributor networks and strategic partnerships in dialysis, critical care, and cardiac surgery at companies such as Baxter, LiDCO, Olive Medical, and most recently, Edwards Lifesciences, a global leader in cardiac devices, critical care medicine, and surgical monitoring.

Dr. Christian Steiner, Vice President of Sales and Marketing of CytoSorbents stated, “We are very pleased to welcome Adrian to our international sales team.  With his expertise in sales and relationship management, extensive international experience, and impressive key opinion leader network in our main markets, Adrian has the perfect background to oversee and drive our distributor and partner sales in Western Europe including those from Fresenius Medical Care and Terumo Cardiovascular.”

Mr. Adrian Thomas stated, “I am delighted to be joining CytoSorbents. The successes of my career have been based on two guiding fundamental principles. First, sell products that can help patients and improve clinical outcomes. Second, focus on technology that is cost-effective and brings value to the hospital and the departments where it is used.  CytoSorb is a unique product that meets both of these requirements in abundance, treating some of the most clinically challenging conditions in medicine today while working to save costs through better care.  I am excited to be part of this rapidly growing company with its strong leadership, a truly innovative therapy, and a core mission to make a difference in the lives of patients worldwide.”

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 17,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites:  https://cytosorbents.com and http://www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

Logo – http://photos.prnewswire.com/prnh/20140408/MM00899LOGO

SOURCE CytoSorbents Corporation